FDA Approves DOXORUBICIN HYDROCHLORIDE LIPOSOME — Baxter Healthcare Company

# FDA Approves Baxter Healthcare's Liposomal Doxorubicin Formulation Baxter Healthcare Company received FDA approval for its liposomal doxorubicin hydrochloride formulation on November 17, 1995, marking a significant advancement in cancer chemotherapy delivery that could reshape the oncology drug market by offering improved pharmacokinetics and potentially reduced cardiotoxicity compared to conventional doxorubicin. The intravenous therapy is expected to capture market share from existing anthracycline treatments while establishing Baxter as a key player